Oncimmune Holdings Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Oncimmune Holdings kazanç ve gelirinin sırasıyla yıllık 100.9% ve 105.1% oranında artması tahmin edilirken, EPS'nin yıllık 32% oranında büyümesi bekleniyor.

Anahtar bilgiler

100.9%

Kazanç büyüme oranı

32.0%

EPS büyüme oranı

Biotechs kazanç büyümesi	42.4%
Gelir büyüme oranı	105.1%
Gelecekteki özkaynak getirisi	n/a
Analist kapsamı	Low
Son güncelleme	21 Oct 2024

Gelecekteki son büyüme güncellemeleri

Recent updates

Kazanç ve Gelir Büyüme Tahminleri

BST:OCY - Analistlerin gelecek tahminleri ve geçmiş finansal verileri (GBP Millions )
Tarih	Gelir	Kazançlar	Serbest Nakit Akışı	Faaliyetlerden Nakit	Avg. Analist Sayısı
8/31/2025	7	0	-1	-1	1
8/31/2024	3	-3	-4	-3	1
2/29/2024	1	-3	-6	-5	N/A
11/30/2023	1	-5	-6	-6	N/A
8/31/2023	1	-6	-7	-7	N/A
8/31/2022	2	-5	-6	-5	N/A
5/31/2022	3	-10	-7	-6	N/A
2/28/2022	4	-8	-7	-6	N/A
11/30/2021	3	-7	-7	-5	N/A
8/31/2021	4	-6	-6	-5	N/A
5/31/2021	4	-5	-6	-5	N/A
2/28/2021	3	-5	-6	-6	N/A
11/30/2020	2	-6	-7	-7	N/A
8/31/2020	1	-7	-8	-8	N/A
5/31/2020	1	-8	-9	-9	N/A
2/29/2020	0	-9	-9	-9	N/A
11/30/2019	0	-9	-9	-9	N/A
8/31/2019	0	-9	-8	-8	N/A
5/31/2019	0	-8	-8	-7	N/A
2/28/2019	0	-8	-7	-7	N/A
11/30/2018	0	-7	-7	-7	N/A
8/31/2018	0	-7	-7	-6	N/A
5/31/2018	0	-6	-6	-6	N/A
2/28/2018	0	-6	-6	-6	N/A
11/30/2017	0	-5	N/A	-5	N/A
8/31/2017	0	-5	N/A	-5	N/A
5/31/2017	0	-5	N/A	-4	N/A
2/28/2017	0	-8	N/A	-4	N/A
11/30/2016	0	-10	N/A	-5	N/A
8/31/2016	0	-9	N/A	-4	N/A
5/31/2016	0	-8	N/A	-3	N/A
5/31/2015	1	-2	N/A	-2	N/A
5/31/2014	1	-1	N/A	-2	N/A

Analist Gelecek Büyüme Tahminleri

Kazançlar ve Tasarruf Oranları: OCY önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Kazançlar ve Piyasa: OCY önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Yüksek Büyüme Kazançları: OCY önümüzdeki 3 yıl boyunca kârsız kalmaya devam edeceği tahmin ediliyor.

Gelir ve Pazar: OCY şirketinin gelirinin (yıllık 105.1% ) German pazarından (yıllık 5.6% ) daha hızlı büyümesi öngörülüyor.

Yüksek Büyüme Geliri: OCY şirketinin gelirinin (yıllık 105.1% ) yıllık 20% dan daha hızlı büyümesi öngörülüyor.

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Gelecekteki ROE: OCY 'un Özsermaye Getirisi'nin 3 yıl içinde yüksek olmasının öngörülüp öngörülmediğini belirlemek için yeterli veri yok

Oncimmune Holdings Gelecekteki Büyüme

Future kriter kontrolleri 2/6

Anahtar bilgiler

Gelecekteki son büyüme güncellemeleri

No longer forecast to breakeven

Oncimmune Holdings plc Reaffirms Revenue Guidance for the Fiscal Year 2024 and Provides Earnings Guidance for the Fiscal Year 2025

Oncimmune Holdings plc Provides Earnings Guidance for the Year 2024

Recent updates

New major risk - Shareholder dilution

No longer forecast to breakeven

New major risk - Financial data availability

Oncimmune Holdings plc Reaffirms Revenue Guidance for the Fiscal Year 2024 and Provides Earnings Guidance for the Fiscal Year 2025

New major risk - Negative shareholders equity

Oncimmune Holdings plc to Report First Half, 2024 Results on May 21, 2024

Less than half of directors are independent

Full year 2023 earnings released: UK£0.085 loss per share (vs UK£0.13 loss in FY 2022)

Oncimmune Holdings plc Provides Earnings Guidance for the Year 2024

Oncimmune Holdings plc, Annual General Meeting, Feb 26, 2024

New minor risk - Financial data availability

Oncimmune Holdings plc Announces Board Changes

Less than half of directors are independent

Oncimmune Holdings plc Announces Changes to the Board

Oncimmune Holdings plc Announces Executive Changes

Freenome Holdings, Inc. acquired Oncimmune Limited and Oncimmune Europe GmbH from Oncimmune Holdings plc (AIM:ONC) for £13 million.

Oncimmune Holdings plc, Annual General Meeting, Feb 27, 2023

Oncimmune Holdings plc Announces Appointment of John Goold as Non-Executive Director

Oncimmune Holdings plc has completed a Follow-on Equity Offering in the amount of £2.1 million.

Less than half of directors are independent

Full year 2022 earnings released: UK£0.14 loss per share (vs UK£0.072 loss in FY 2021)

Now 20% undervalued after recent price drop

Oncimmune Holdings plc Announces Board Changes

Less than half of directors are independent

First half 2022 earnings: EPS in line with expectations, revenues disappoint

Oncimmune Holdings Ordinary Shares to Be Deleted from Other OTC

Oncimmune Holdings plc Announces EarlyCDT Lung Test Approved by Ministry of Health for Aragon, Spain

Full year 2021 earnings released: UK£0.072 loss per share (vs UK£0.13 loss in FY 2020)

Oncimmune Holdings plc Announces the Pre-Publication of the First Results from Its Collaboration with Cedars-Sinai Medical Center in Los Angeles

Oncimmune Holdings plc Presents Clinical Abstracts on Melflufen At the 2021 American Society of Clinical Oncology

Oncopeptides AB (publ) Presents New Clinical and Preclinical Melflufen Data At the Upcoming European Hematology Association Meeting

First half 2021 earnings released: UK£0.041 loss per share (vs UK£0.083 loss in 1H 2020)

New 90-day high: €2.12

Oncimmune Holdings plc to Report First Half, 2021 Results on Feb 15, 2021

Oncimmune Holdings plc Announces Steps Down of Cheung to as a Non-Executive Director, Effective 19 January 2021

New 90-day high: €2.04

Oncimmune Holdings plc Signs Commercial Contracts

New 90-day high: €1.99

Oncimmune Holdings plc, Annual General Meeting, Nov 30, 2020

Full year earnings released - €0.13 loss per share

Annual earnings released: Revenue misses expectations

Oncimmune Holdings plc to Report Fiscal Year 2020 Results on Oct 30, 2020

Oncimmune Holdings plc Initiates U.S. Expanded Access Program with Melflufen in Triple-Class Refractory Multiple Myeloma

Oncimmune Holdings plc announced that it has received £5.25 million in funding from Balderton Capital (UK) LLP and other investors

Oncimmune Holdings plc Signs Collaboration with Genentech

New 90-day high - €1.55

New 90-day high - €1.45

Kazanç ve Gelir Büyüme Tahminleri

Analist Gelecek Büyüme Tahminleri

Hisse Başına Kazanç Büyüme Tahminleri

Gelecekteki Özkaynak Getirisi

Büyüyen şirketleri keşfedin